Dr Jason Butler

Clinical Haematologist
Become a Patient


Dr Jason Butler is a clinical haematologist at Icon Cancer Centre South Brisbane and Icon Cancer Centre Chermside.

Dr Butler completed his dual training in clinical and laboratory haematology in 2004 following a research posting at the Queensland Institute of Medical Research investigating the role of bcl-2 in primary resistance in chronic myeloid leukaemia. Following a fellowship year at the Bone Marrow Transplant Unit, Royal Brisbane and Women’s Hospital, he has been, until recently, a full-time senior staff specialist with that unit. In addition, he has provided outreach clinic support to the Nambour General Hospital and locum tenens roles for Icon. Dr Butler also completed a Masters in Medical Science (Clinical Epidemiology) to assist with development of investigator-initiator research studies.

His major clinical interests are in all aspects of malignant blood disorders particularly in leukaemia, lymphoma, and myeloma, as well as autologous and allogeneic stem cell transplantation. Dr Butler also undertakes other roles, including extensive educational support and clinical presentations for patients and health professionals, and advocacy roles as a board member for Lymphoma Australia.

Affiliations & Memberships

  • Royal Australasian College of Physicians (RACP)
  • Royal College of Pathologists of Australasia (RCPA)
  • Australian Medical Association (AMA)
  • Australasian Leukaemia and Lymphoma Group (ALLG)
  • European Haematology Association (EHA)
  • American Society of Haematology (ASH)

Special Interests

Dr Jason Butler accepts referrals for malignant and non-malignant blood disorders, with a special clinical interest in:
  • Haematology
  • Leukaemia
  • Lymphoma
  • Multiple myeloma
  • Stem cell transplantation

Icon Locations

South Brisbane View centre
Chermside View centre


  • Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Niederwieser, D., Or, R., Szer, J., Wagner, E. M., Zuckerman, T., Mahuzier, B., Xu, J., Wilke, C., Gandhi, K. K., Socié, G., & REACH2 Trial Group (2020). Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. The New England journal of medicine, 382(19), 1800–1810.

  • Fowler, N. H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L., Chavez, J. C., Bachy, E., Kato, K., Harigae, H., Kersten, M. J., Andreadis, C., Riedell, P. A., Ho, P. J., Pérez-Simón, J. A., Chen, A. I., Nastoupil, L. J., von Tresckow, B., … Thieblemont, C. (2022). Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nature medicine, 28(2), 325–332.